The United Kingdom and the United States have announced a landmark trade agreement that will keep no duties on UK pharmaceutical shipments being sold in the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to increase expenditure on medicines through the NHS. This commitment secures that duties on these key goods will be held at nothing for a period of three years.
This agreement comes after previous statements to dramatically increase import taxes on branded pharmaceutical products, with potential rates floated up to double the cost.
"This deal between the United Kingdom bolsters the worldwide climate for cutting-edge drugs and establishes long-overdue fairness to American-British pharmaceutical trade," an announcement noted.
Trade Significance
Medicines represent one of the Britain's largest goods shipped to the America, which is easily the primary market for leading companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period to the end of last September, the UK exported pharmaceutical products totaling over eleven billion pounds to the US. This amount accounted for nearly one-fifth of British export trade in that timeframe.
"This guarantee safeguards jobs, boosts capital expenditure and paves the way for the UK to establish itself as a international leader for biotech and pharma," a minister stated.
Specific UK Commitments
The agreement includes several key pledges from the UK:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it deems new treatments to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a goal to double total public funding on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The sum pharmaceutical firms must refund to the NHS to prevent overspending will be capped at fifteen percent. In the past, rebates topped 20%.
Recent Tensions
The deal follows a protracted tension between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
These tensions were intensified by claims that American consumers were charged significantly more for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been paused or cancelled, while multi-billion-dollar funding commitments have been directed toward American operations.
The Science Minister acknowledged that the NHS must spend more on treatments, noting that its budget allocation on drugs had shrunk as a share of its overall budget over the previous ten-year period.
